Inhibrx, Inc. announced today that the Company will be presenting three poster presentations at the Society for Immunotherapy of Cancer’s (SITC) annual meeting, to be held in Washington, D.C.
SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Inhibrx, Inc.. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the Company will be presenting three poster presentations at the Society for Immunotherapy of Cancer’s (SITC) annual meeting, to be held in Washington, D.C. and in a virtual platform, on November 10-14, 2021. “We are excited to share some of the preclinical data related to our clinical candidates, INBRX-105 and INBRX-106, which inform the selection of pharmacodynamic biomarkers, dosing and clinical strategy,” said Brendan Eckelman, Ph.D., Inhibrx Co-founder and Chief Scientific Officer. Poster Presentation Details: Title: INBRX-106: A novel hexavalent anti-OX40 agonist for the treatment of solid tumors Title: INBRX-105- Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4-1BB agonist Title: INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities The scientific posters will be accessible through the following link on the investors section of Inhibrx’s website at https://inhibrx.investorroom.com/events-and-presentations. About Inhibrx, Inc. Investor and Media Contact: Kelly Deck
SOURCE Inhibrx Inc. | ||
Company Codes: NASDAQ-NMS:INBX |